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Abstract: Two new complexes with the general formula 
[Cu2(L)tpmc](ClO4)3·nH2O (tpmc = N,N′,N′′,N′′′-tetrakis(2-pyridylmethyl)- 
-1,4,8,11-tetraazacyclotetradecane, L = N-methylglycine, n = 3; L = N,N- 
-dimethylglycine, n = 2) were isolated and their composition, some physical 
and chemical properties and geometries were proposed based on elemental 
analysis (C, H, N), conductometric and magnetic measurements and spectro-
scopic data (UV–Vis, FTIR). It is evident that the complexes are binuclear and 
an exo coordination mode of the macrocyclic ligand in the boat conformation 
was proposed. The co-ligands are coordinated as a bridge using both oxygen 
atoms of the OCO- group. The cytotoxic activity of Cu(II) complexes as well 
as their Co(II) analogs, the starting ligands and the free salts were tested 
against human cervix adenocarcinoma cell line (HeLa), human chronic myelo-
genous leukemia cells (K562), human breast cancer cell line (MDA-MB-453), 
and a non-cancerous cell line, human embryonic lung fibroblast (MRC-5). The 
IC50 values for the Cu(II) complexes were from 21.6±0.04 to 66.1±0.8, and for 
the Co(II) analogs were within the range from 8.8±0.74 to 15.40±1.52. All four 
complexes were tested for their antimicrobial activity against Staphylococcus 
aureus, Bacillus subtilis, Escherichia coli and the yeast Candida albicans. 
Keywords: Cu(II) and Co(II) complexes; octaazamacrocycle; antiproliferative 
activity; antimicrobial activity. 
INTRODUCTION 
The serious medical problem of bacterial and fungal resistance and the rate 
at which it develops have led to increasing levels of resistance to classical anti-
biotics. An urgent task for infectious diseases research programs have become 
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the discovery and development of effective antibacterial and antifungal drugs 
with novel mechanism of action.1 Currently, cancer rates continue to dramatic-
ally increase and pose a serious threat to public health. Although many anti-
tumor agents have been developed in the recent years, the survival rate of pati-
ents is not satisfactory.2 There is a strong relationship between metals or their 
complexes, and their antibacterial, antitumor, and anticancer activities. A number 
of in vivo studies have indicated that biologically active compounds become 
more bacteriostatic and carcinostatic upon chelation.3 A number of metal com-
plexes of amino acid with transition metals possess anticarcinogenic activity. 
Amino acids have been effectively used to direct nitrogen mustards into cancer 
cells.4 The design and synthesis of mixed ligand coordination complexes of 
Cu(II) and Co(II) have received considerable attention.5 Macrocyclic structures 
are extremely favorable for metal complexation,6 especially polyazamacrocyclic 
chelating ligand cyclams and cyclam-derived such as tpmc (N,Nʹ,Nʹʹ,Nʹʹʹ-tetra-
kis(2-pyridylmethyl)-1,4,8,11-tetraazacyclotetradecane). Numerous mixed-ligand 
Cu(II) and Co(II) complexes containing pendant macrocycle tpmc and one or two 
additional ligands of various type are applied as antitumor,7,8 antiviral, anti-
HIV,9 antibacterial, antifungal or antimalarial agents.10–13 Depending on the 
reaction conditions, and structure and number of the co-ligands, the macrocycles 
have the possibility to form mono-, bi- and tetranuclear transition metal com-
plexes. On the other hand, it is a fact that amino acids or their derivates are 
attractive ligands due to their biological activity (acids are the building blocks of 
proteins and participate in all major processes in organisms). Therefore, they are 
often used as ligands in the synthesis of coordination compounds. Amino acids, 
like other aminocarboxylato ligands, are bonded in one of many modes, i.e., as 
N-monodentate; N,O-bonded as chelate in mononuclear complexes or in binuc-
lear ones as bridging ligands between the two metallic centers in the N,O,Oʹ- 
-mode. In addition, one or both oxygen atoms may be included in the coordin-
ation and the –NH2 group remains uncoordinated. There are various possibilities 
for bonding. They can coordinate non-symmetrically, symmetrically or in a com-
bined chelate-bridged manner.14 Sarcosine (N-methylglycine) is an amino acid 
occurring in various living organisms as an intermediate in amino acid meta-
bolism and as a component of peptides. Additionally, it can potentially serve as a 
liposome cryoprotectant and as a drug for treatment of schizophrenia.4 In pre-
vious papers, the synthesis and the properties of mixed-ligand Co(II) complexes 
with the general formula [Co2(Y)tpmc]Z (HY= glycine or N-methylglycine/N,N- 
-dimethylglycine, Z = BF4– or ClO4–) were described.15 They crystallized with 
different amounts of crystal solvents (H2O/CH3CN). In continuation of this res-
earch, two new Cu(II) complexes with mixed ligands of macrocycle tpmc and the 
same amino acid derivate co-ligands were synthesized. The structures of the 
compounds were proposed based on spectral (UV–Vis and IR) and elemental 
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analysis (C, H, N) data. The complexes were characterized by conductometric 
and magnetic measurements. The antimicrobial and antiproliferative activities of 
the new Cu(II) and the previously prepared Co(II) complexes with the same lig-
ands15 were tested and the relationship between the biological activities of all 
complexes and their structures are discussed. 
EXPERIMENTAL 
Chemicals and materials. Ligand tpmc and complexes [Cu2tpmc](ClO4)4,  
[Co2(N-mgly)tpmc](BF4)3·4H2O (3) and [Co2(N,N-dmgly)tpmc](BF4)3·3H2O (4), were pre-
pared and purified as described in the literature.15-17 The other chemicals: N-methylglycine 
(N-mgly) and N,N-dimethylglycine (N,N-dmgly), CH3OH and NaOH as p.a. commercial 
products were provided by Merck, while 1,4,8,11-tetraazacyclotetradecane (cyclam), 2-picolyl 
chloride hydrochloride, penicillin, streptomycin, nutrient medium RPMI-1640, DMSO and 
0.05 % triphenyltetrazolium chloride (TTC) were obtained from Sigma–Aldrich and the fetal 
bovine serum (FBS) was obtained from Biochrom AG (Berlin, Germany). 
Preparation 
Caution! Perchlorate complexes are potentially explosive.  
General procedure. The complex [Cu2tpmc](ClO4)4 (0.050 g/0.50 mmol) was dissolved 
in 5 mL of CH3OH under continuous stirring and refluxed in a water bath (80 °C). The sol-
ution of the co-ligand N-methylglycine or N,N-dimethylglycine (0.0688 g/0.0788 g; 0.75 
mmol) in CH3OH was added to the hot solution of [Cu2tpmc](ClO4)4. The pH of the solution 
was adjusted to 6 using 0.1 M NaOH. The reaction mixture was continuously stirred and 
refluxed for the following 5 h. Finally, the solvent was evaporated to 1/4 of the initial volume. 
The solution was left in a refrigerator overnight, until precipitation of the solid blue micro-
crystalline product occurred. The precipitate was separated by suction, washed properly with 
small portions of cold water and dried at room temperature. The product was purified by 
recrystallization from methanol. 
[Cu2(N-mgly)tpmc](ClO4)3·3H2O (1). Yield: 77 mg (68 %); Anal. Calcd. for 
C37H56N9O17Cu2Cl3 (FW = 1132.50): C, 39.23; H, 4.41; N, 11.13 %. Found: C, 39.02; H, 
4.17; N, 10.66 %.  
[Cu2(N,N-dmgly)tpmc](ClO4)3·2H2O (2). Yield: 82 mg (73 %); Anal. Calcd. for 
C38H56N9O16 Cu2Cl3 (FW = 1128.43): C, 40.44; H, 4.90; N, 11.16 %. Found: C, 40.70; H, 
4.46; N, 10.78 %.  
At room temperature, the complexes are soluble in CH3OH and insoluble in H2O. 
Analytical spectral and other physical measurements. The elemental analyses were per-
formed by standard methods. The electronic absorption spectra of the complexes in CH3OH 
solution (c = 1.0×10-3 M) were recorded on a GBC UV–Vis spectrophotometer Cintra 20. The 
FTIR spectra were recorded on a Nicolet 6700 FTIR (ATR technique) in the range of 400– 
–4000 cm-1. The molar conductivities were measured using HANNA instruments HI 8820N 
conductometer (at 20±2 °C) in CH3OH (c = 1.0×10-3 M). The magnetic susceptibilities were 
measured on an MSB-MKI magnetic balance, Sherwood Scientific Ltd., England, at room 
temperature (20±2 °C). The data were corrected for diamagnetism using Pascal’s constants.18 
In vitro evaluation of antimicrobial and antiproliferative activity  
Antimicrobial activity. The antimicrobial activity of the new complexes Cu(II) (1 and 2) 
and the Co(II) analogs [Co2(N-mgly)tpmc](BF4)3·4H2O (3) and [Co2(N,N-dmgly)tpmc](BF4)3·3H2O 
(4), were assayed using the broth-microdilution method against the following laboratory 
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strains obtained from the American Type Culture Collection (ATCC): Gram-positive bacteria 
Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 6633, Gram-negative 
bacteria Escherichia coli ATCC 25922 and one strain of the yeast Candida albicans ATCC 
10231. Stock solutions (10 mM) of the compounds were prepared in dimethyl sulfoxide 
(DMSO), and diluted to the working concentrations in fresh Müller–Hinton broth for bacteria 
and Sabouraud broth for C. albicans. Bacterial and yeast suspensions were prepared by the 
direct colony method. The colonies were taken directly from the plate and suspended in 5 mL 
of sterile 0.85 % saline. The turbidity of the initial suspension was adjusted by comparing it to 
0.5 McFarland’s standard. When adjusted to the turbidity of the 0.5 McFarland’s standard, the 
bacterial suspension contained about 108 colony forming units, CFU mL-1, and the suspension 
of yeast contained 106 CFU mL-1. Ten-fold dilutions of the initial suspension were addition-
ally prepared into Müller–Hinton broth for the bacteria and Sabouraud broth for C. albicans. 
Each dilution of complexes was poured in triplicates into a 96-well microtiter plate and ino-
culated with previously prepared bacterial suspension. For a negative control for each plate, 
only the medium was used. As a positive control of growth, wells containing only the micro-
organisms in the broth were used. In addition, the activity of the starting compounds: 
[Cu2tpmc](ClO4)4, tpmc, N-methylglycine and N,N-dimethylglycine were also tested. The 
MICs of ampicillin, and nystatin were determined in parallel experiments. In the tests, 0.05 % 
TTC was also added to the culture medium as a growth indicator. TTC is a redox indicator 
used for differentiation between metabolically active and non-active cells. The colorless 
compound is enzymatically reduced to red 1,3,5-triphenylformazan by cell dehydrogenases, 
indicating metabolic activity (red color of the medium in microtiter plate well). The bacteria 
growth was determined after 24 h, while the growth of C. albicans was determined after 48 h 
of incubation at 37 °C. The lowest concentration of the extract at which the microorganism 
does not demonstrate visible growth (МIC) and the minimal bactericidal or fungicidal concen-
tration (MBC) were determined in broths from each well (10 mL) and inoculated in Müller– 
–Hinton agar for 24 h at 37 °C for bacterial strains, and in Sabouraud dextrose agar for 48 h at 
26 °C for the fungi. All determinations were performed in triplicate.  
Antiproliferative activity 
Preparation of stock solutions of the test compounds. The solutions of the investigated 
compounds (1–4), the starting ligands and the free salts were prepared in dimethyl sulfoxide at 
concentrations of 10 mM, and diluted by nutrient medium to working concentrations. The 
complete nutrient medium RPMI-1640 was supplemented with 10 % fetal bovine serum, 2 
mM L-glutamine and 1 % penicillin/streptomycin. 
Cell lines. Human cervix adenocarcinoma cell line (HeLa), human chronic myelogenous 
leukemia cells (K562), human breast cancer cell line (MDA-MB-453), and the non-cancerous 
cell line, human embryonic lung fibroblast (MRC-5) were grown in complete RPMI-1640 
medium. 
Determination of cell survival. Targeted adherent cells HeLa (2,500 cells/well), MDA- 
-MB-453 (3,000 cells/well) and MRC-5 (5,000 cells/well) were seeded into the wells of a 96- 
-well flat-bottomed microtiter plate. Twenty-four hours later, after cell adhesion, different 
concentrations of examined compounds were added to the wells, except for the controls, 
where only the complete medium was added. For non-adherent K562 cells (6,000 cells/well), 
the extracts were applied 2 h after the cell seeding. Culture medium with corresponding con-
centrations of the investigated compounds, but without the cells, was used as blank. The cul-
tures were incubated for 72 h, and the effects of the investigated compounds on cancer and 
normal cell survival were determined using the microculture tetrazolium test (MTT), accord-
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ing to Mosmann19 with modification by Ohno and Abe,20 72 h after the addition of the inves-
tigated compounds. Briefly, 20 µL of MTT dye solution (5 mg mL-1 of 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide in phosphate-buffered saline) was added to 
each well. Samples were incubated for an additional 4 h at 37 °C in a humidified atmosphere 
of 5 vol.% CO2. Afterward, 100 mL of 10 % sodium dodecyl sulfate (SDS) were added in 
order to extract the insoluble formazan, which represents the product of the conversion of the 
MTT dye by viable cells. The number of viable cells in each well is proportional to the 
intensity of the absorbance (A) of light, which was measured in microtiter plate reader at 570 
nm, 24 h later. To determine cell survival (S%), the A of a sample with cells grown in the 
presence of various concentrations of the investigated compounds was divided by the control 
optical density (the A of control cells grown only in nutrient medium) and multiplied by 100. 
The A of the blank was always subtracted from the A of the corresponding sample incubated 
with the target cells. All experiments were performed in triplicates.  
RESULTS AND DISCUSSION 
The reaction conditions were carefully adjusted by controlling the pH and 
temperature. Under these conditions the mixture of the solutions of 
[Cu2(tpmc)](ClO4)3 and N-methyl/N,N-dimethylglycine in CH3OH in a molar 
ratio 1:1.5 resulted in blue microcrystalline products presented by general for-
mula [Cu2(L)tpmc] (ClO4)3·nH2O. With L = N-methylglycine, the water content 
was n = 3 (1), while with L = N,N-dimethylglycine n = 2 (2). The yields were 68 
and 73 %, respectively. The results from the elemental analyses are in accordance 
with the proposed dinuclear structure. The physical characteristics of the 
obtained compounds and related Co(II) complexes are presented in Table I. The 
molar conductivity values 350 and 395 S cm2 mol–1 for 1 and 2, respectively in 
CH3OH (1.0×10–3 M) are in agreement with the values for 1:3 type electrolytes.21 
TABLE I. Magnetic moment at room temperature, electronic spectral data and molar conduct-
ivity in CH3OH (c = 1.0×10-3 M) for new Cu(II) complexes compared with some Co(II) 
analogues 
Complex λmax / nm  (ε / dm3 mol-1 cm-1) 
μeff / μB 
per Cu(II) 
Λm 
S cm2 mol-1 
[Cu2(N-mgly)tpmc](ClO4)3·3H2O (1) 640 (316) 1.86 350 
[Cu2(N,N-dmgly)tpmc](ClO4)3·2H2O (2) 683 (558) 1,80 395 
[Co2(N-mgly)tpmc](BF4)3·4H2O (3)15 455(30) 508(53) 544(35) 4.77 360 
[Co2(N,N-dmgly)tpmc](BF4)3·3H2O (4)15 487(38) 510(42) 546(28) 4.70 366 
Magnetic properties. The magnetic moment values for Cu(II) complexes are 
1.86 (for 1) and 1.80 μB (for 2) at room temperature (see Table I). These data are 
consistent with one unpaired electron in paramagnetic pentacoordinate Cu(II) 
complexes.22 In similar 5-coordinated Cu(II) complexes with carboxylate co-lig-
ands the values of the magnetic moments are in the range of 1.75–2.20 
μB/Cu(II).14,23–25 However, similar values are reported for binuclear Cu(II) com-
plexes with no magnetic interaction between the copper(II) ions as well.23–25 
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Spectroscopic properties 
UV–Vis. The electronic absorption spectra in methanol of 1 and 2 show a 
broad maximum at 640 and 683 nm and molar absorption coefficients (ε) of 316 
and 558 M–1 cm–1 (Table I). The large width of the spectral bands, the position 
of λmax, and the shapes correspond to d–d transitions of the Cu(II) complexes.26 
The similarity of these spectra to the spectra of the related aminocarboxylate 
complex with S-phenylalanine and with numerous carboxylate Cu(II) com-
plexes14,23–25 additionally supports the proposed five-coordinate geometry of 
Cu(II). There is a bathochromic shift of the absorption maximum in the case of 
complex 2 in comparison to complex 1. This could be ascribed to the fact that the 
–CH3 group/s at the N atom affects the strength of the ligand field in the amino-
carboxylate derivatives. Based on these data, it was concluded that in both com-
plexes the co-ligands are coordinated in the same way. The chromophore indi-
cates that the co-ligands are coordinated via the OCO– group. The value of the 
molar coefficient of absorptivity, ε, which decreases with increasing symmetry of 
the molecules, was found in similar complexes.26 The lower value of ε in com-
plex 1 indicates its higher symmetry compared to complex 2 (see Table I). In the 
UV part of the electronic spectra, very intensive multiple bands, ascribed to CT 
appeared in the 205–330 nm range (ε was in the range 5000–5700 M–1 cm–1) for 
the N-mgly and N,N-dmgly complexes.  
FTIR spectra. In the infrared spectra of the newly synthesized complexes (1 
and 2), containing N-methylglycinato/N,N-dimethylglycinato anions, the follow-
ing bands were found: a broad multiple band of 3586/3590 cm–1 arising from 
ν(O–H), indicating the presence of a water molecule; a band at 3439 cm–1 of 
ν(NH) for the secondary amino group excluded from coordination in complex 1; 
bands at 3090/3084 cm–1 ν(C–H) from pyridine rings; a weak broad band in the 
range of 2963–2894 cm–1 likely showing stretching vibration of CH; and two 
medium bands about 1440 and 1490 cm–1 due to CH2 bending vibrations; a sharp 
strong band at 1611/1613 cm–1 from the skeletal stretching valence vibration of 
the tpmc pyridine included in coordination that was found at 1588 cm–1 in the 
spectrum of free tpmc; a broad intensive band at 1096/1094 cm–1 from ν(ClO4) 
and a medium sharp band at around 623/622 cm–1 from δ(ClO4) for both com-
plexes. In the low-frequency region, in the spectra of both complexes, the bands 
are in the range 462/466 cm–1 and in the range 418/419 cm–1, which are attri-
buted to the existence of Cu–O and Cu–N bonds, respectively, with the cop-
per(II) ions.27 These vibrations confirm the coordination of ligands to the central 
metal ions and the involvement of nitrogen (from tpmc) and oxygen atom (OCO– 
from N-mgly/N,N-dmgly) in the coordination. The aminocarboxylic acid ligands 
feature multiple coordination sites that combine the characteristics of amine and 
carboxylic groups and are able to exhibit different coordination modes depending 
on the nature of the reaction system. The FTIR spectra of complexes and ligands 
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show strong evidence in support of the involvement of carboxylate group from 
N-mgly/N,N-dmgly in the coordination. In comparison to the free amino acids 
derivatives, νas(OCO–) and νs(OCO–) bands were shifted, which confirm the 
coordination of the carboxylate group. The difference in the FTIR stretching fre-
quencies of the bound carboxylate complexes, ∆ν(OCO–) between the observed 
asymmetric, νas(OCO–) and the symmetric, νs(OCO–) bands provide useful 
information about the different binding modes of the coordination carboxylate 
ligands. The absorption band due to νas(OCO–) and νs(OCO–) appear at 1574 
and 1375 cm–1 for (1) and 1573 and 1376 cm–1 for (2), respectively. The band 
assigned to the carboxyl group is red shifted compare to the free ligand thus indi-
cating coordination to the metal. The changes of the Δν = νas – νs values for the 
complexes compared with those found for their corresponding aminocarboxylate 
derivatives showed that OCO– group is also coordinated to Cu(II).28 The obs-
erved range is in accordance with the values reported for coordinated OCO– 
stretching bands in amino–carboxylate Cu(II) tpmc complexes.25 A comparison 
of the difference Δν = 199 cm–1 (for 1) and Δν = 197 cm–1 (for 2) with the 
“ionic” value for Na-N-mgly (Δν = 190 cm–1) and Na-N,N-dmgly (Δν = 218 cm–1) 
suggests bridge coordination modes of the OCO– group.27,28 It could be con-
cluded that in both complexes, the ligands are coordinated as a bridge using both 
oxygen atoms COO– group. The most probable way of coordination of the car-
boxyl group is μ-O,Oʹ as in Cu(II) complexes with bridge S-phenylalanine as 
well as with other carboxylate co-ligands (benzoate and phthalate).14,23,25 Mono-
dentate coordination of the OCO– group could be excluded (in this case, Δν 
would be much larger in the complex compared to the ligand) as well as the chel-
ate-bridged binding (Δν was much less in the complex compared to the lig-
and).27,28 The participation of the amino nitrogen in the coordination for Cu(II) 
is excluded in both complexes. The substitution of the amino group of glycine 
with –CH3 group reduces the probability of coordination of atom N even though 
its donor properties increase. However, due to steric disturbances, this is highly 
unlikely. The existence of the zwitter ion of aminocarboxylate derivatives and its 
coordination for Cu(II) cannot be excluded using the applied methods. In the 
Co(II) analogs, the anions of N-methyl derivatives are also coordinated through 
OCO–, in a combined chelate-bridged manner (∆ν values in Co(II) complexes 
were significantly lower than in the spectra of the respective free co-ligand). 
From all the data presented, it is presumed that the two newly synthesized com-
plexes are binuclear with an exo coordination mode of the macrocyclic pendant 
ligand in the boat conformation. Each Cu(II) ion is coordinated by five donor 
atoms using the two pyridyl and two cyclam nitrogens of tpmc and the oxygen 
atom of the co-ligand. The participation of the co-ligand nitrogen atom is 
excluded. Probably both oxygens of OCO– are engaged in the coordination thus 
forming a bridge between two metal ions from the same tpmc unit, Fig. 1. 
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Fig. 1. Proposed structure of complex cations: a) [Cu2(N-mgly)tpmc]3+of 1a and  
b) [Cu2(N,N-dmgly)tpmc]3+of 2b. 
Antibacterial and antiproliferative activity 
Antimicrobial activity. The increasing drug resistance of microorganisms is 
becoming a serious threat for countering microbial infections. New, more effect-
ive therapies and alternative substances, such as coordination complexes, that are 
effective against highly resistant strains are still being sought.29 The results for 
the in vitro antimicrobial activity of the new complexes and previously described 
Co(II) analogs are given in Table II.  
TABLE II. Antimicrobial activity of the tested complexes (1–4) and referent antibiotics, 




1 2 3 4 Ampicillin Nystatin 
S. aureus 275.75 274.75 141.56 141.00 2.4 n.t. 
B. subtilis 275.75 274.75 283.13 282.00 4.8 n.t. 
E. coli >1000 >1000 >1000 >1000 4.8 n.t. 
C. albicans >1000 >1000 >1000 >1000 n.t. 3.125 
The Cu (II) and Co (II) complexes with amino acid derivatives did not show 
activity against the Gram-(–) bacteria and the yeast C. albicans. All four tested 
complexes showed activity against Gram-(+) bacteria. This could be explained 
by the difference in the permeability of the membrane of Gram-(+) bacteria in 
comparison to the Gram-(–) one due to the difference in their structure.30 Gram- 
-(+) bacteria are known to be more susceptible to amino acids complexes.31 Lite-
rature data show that bimetallic complexes of sarcosine with Zn(II) and Sn(IV) 
are more active against Gram-(+) bacterial strain than against Gram-(–) bac-
teria.34 Several studies have used a classification based on the MIC results to 
evaluate the antimicrobial activity of new compounds as: good, MIC less than 
100 μg mL–1; moderate: MIC between 100 and 500 μg mL–1; weak: MIC 
between 500 and 1000 μg mL–1; and inactive when the MIC value is more than 
1000 μg mL–1.32 In this way, it was possible to evaluate the antimicrobial acti-
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vity of the examined metal complexes as moderate (Table III). Furthermore, 
when the MBC/MIC ratio is less than or equal to 4.0, the investigated agent 
would be considered as bactericidal, and when this ratio is more than 4.0 should 
be considered as bacteriostatic. The examined compounds showed bactericidal 
effect on S. aureus and B. subtilis. 
TABLE III. Minimal bactericidal concentration (MBC / μg mL-1) and MBC/MIC ratio (in 
parentheses) for the tested complexes 1–4 
Bacterium Complex 
1 2 3 4 
S. aureus 275.75 (1) 549.50 (2) 283.13 (2) 141.00 (1) 
B. subtilis 551.50 (2) 1099.0 (4) 283.13 (1) 282.00 (2) 
Antiproliferative activity. The in vitro antiproliferative activities of com-
pounds 1–4, tpmc and co-ligands were evaluated against cell lines Human cervix 
adenocarcinoma (HeLa), human chronic myelogenous leukemia (K562), human 
breast cancer (MDA-MB-453), and a non-cancerous cell line, human embryonic 
lung fibroblast (MRC-5) by the MTT colorimetric assay method. The obtained 
IC50 values (concentration of compounds that induced a 50 % decrease in cell 
survival) are given in Table IV together with the activity of cisplatin as the ref-
erent cytostatic drug. All four compounds promoted a significant decrease in the 
metabolic activity of the HeLa, K562, MDA-MB-453 and MRC-5 cells, which 
occurred in a dose-dependent manner (cell survival, S vs. concentration of com-
pounds, Fig. 2). The IC50 values of the complexes were in the range of 8.80–66.1 
µM against the four tested cell lines, while for cisplatin, they were in the range 
5.82–8.63 µM (Table IV). On the other hand, compounds 1 and 2 showed moder-
ate activity, regarding all four cell lines. However, compounds 3 and 4 showed 
excellent antiproliferative activity against the investigated cells. On the contrary, 
compounds: tpmc, starting salts and free ligands did not show cytotoxic activity 
(IC50 > 200 µM) under the same conditions. The obtained results are in agree-
ment with data indicating that cobalt-containing complexes are very promising as 
TABLE IV. IC50±SD values (µM) after 72 h of action of the investigated complexes 1–4, 
ligands and cisplatin on the tested cell lines, determined by the MTT test 
Complex Cell line HeLa K562 MDA-MB-453 MRC-5 
[Cu2(N-mgly)tpmc](ClO4)3·3H2O (1) 66.1±0.8 64.2±1.2 44.9±2.1 45.6±0.1 
[Cu2(N,N-dmgly)tpmc](ClO4)3·2H2O 
(2) 
40.6±1.7 38.0±1.54 37.8±0.3 21.60±0.04 
[Co2(N-mgly)tpmc](BF4)3·4H2O (3) 15.40±1.52 9.70±0.28 12.68±1.02 9.51±1.00 
[Co2(N,N-dmgly)tpmc](BF4)3·3H2O (4) 11.88±0.40 10.66±0.88 13.43±1.25 8.80±0.74 
Tpmc, N-mgly, N,N-dmgly >200 >200 >200 >200 
Cisplatin 6.90±1.71 5.82±0.17 6.73±0.48 8.63±1.38 
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potential antitumor agents.32 It was observed that the Co(II) complexes have a 
higher cytotoxic activity than the Cu(II) complexes. This is also the case with 
complexes 1–4. The data presented in the Table IV show that the IC50 values for 
the MRC-5 cell line are similar to the ones obtained for cisplatin. 
 
Fig. 2. Dose-response curves for the cytotoxicity of complexes 1–4 toward HeLa, K562, 
MDA-MB-453 and MRC-5 cells. 
Due to the similarity of the structures of the Co(II) and Cu(II) complexes, 
the different antimicrobial activity could be explained by electronic and steric 
factors. The distribution of the molecular force in the molecule depends on the 
co-ligand and reduces the antiproliferative activity. In addition, the bridging of 
two metal centers by one co-ligand modifies the geometry of the whole molecule. 
A particular geometric shape could facilitate the contact with microorganisms 
and rapidly inhibit their growth if there are no steric disturbances by the ligands. 
The strength of the M–O bonds in the above described complexes is a con-
sequence of various factors, such as, steric repulsions between the alkyl groups 
from the aminocarboxylates/derivatives and the pyridyl groups from tpmc, 
changes the inductive effects of the introduced –CH2–/–CH3 groups and their 
positions, the size of the alkyl group in relation to the size of the macro-cyclic 
cavity, non-covalent interactions, etc. It is difficult to determine the contribution 
of each factor, as they are all responsible for the overall structure. The influence 
of the described factors on cytotoxicity is significant, but nevertheless the most 
significant influence is that of the central ion. 
CONCLUSIONS 
In this article, the synthesis, spectroscopic, magnetic properties of new 
Cu(II) mixed-ligand complexes with octaazamacrocyclic ligand tpmc and glycine 
derivatives, N-methylglycine and N,N-dimethylglycine, were reported. From all 
the obtained data, it could be concluded that two new synthesized complexes are 
binuclear with an exo coordination mode of the macrocyclic pendant ligand in the 
boat conformation. Each Cu(II) ion is coordinated by five donor atoms using two 
pyridyl and two cyclam nitrogen atoms of tpmc and the oxygen atom of the 
co-ligand. The participation of the nitrogen of co-ligand atom was excluded. Pro-
bably, both oxygens of OCO– are engaged in coordination thus forming a bridge 
between two metal ions from the same tpmc unit. The results for the antibacterial 
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activities for the new Cu(II) complexes and Co(II) analogous show that they have 
bacteriostatic activity, while the antiproliferative activity is moderate for Cu(II) 
complexes, whereas Co(II) complexes showed excellent cytotoxic activity 
against the four tested human cell lines.  
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И З В О Д  
СИНТЕЗА И КАРАКТЕРИЗАЦИЈА БАКАР(II) КОМПЛЕКСА СА ДЕРИВАТИМА 
ГЛИЦИНА. in vitro АНТИПРОЛИФЕРАТИВНА И АНТИМИКРОБНА ЕВАЛУАЦИЈА 
Cu(II) И Co(II) АНАЛОГА 
БРАНКА ДРАЖИЋ1, МИРЈАНА АНТОНИЈЕВИЋ НИКОЛИЋ2, ЖЕЉКО ЖИЖАК3 и СЛАЂАНА ТАНАСКОВИЋ2 
1Фармацеутски факултет, Универзитет у Београду, Војводе Степе 450, 11000 Београд, 2Висока 
медицинска и пословно-технолошка школа струковних студија, Хајдук Вељкова 10, 15000 Шаба, и 
3Институт за онкологију и радиологију Србије, Пастерова 14, Београд 
Синтетисана су два нова комплекса општe формулe [Cu2(L)tpmc](ClO4)3·nH2O (tpmc 
= N,N′,N′′,N′′′-тетракис(2-пиридилметил)-1,4,8,11-тетраазациклотетрадекан, L = N-мет-
илглицин, n = 3; L = N,N-диметилглицин, n = 2) а њихов састав, неке физичке и хемијске 
особине и геометрија су предложени на основу елементалне анализе (C, H, N), кондук-
тометријских и магнетних мерења и спектроскопских података (UV–Vis, FTIR). Утвр-
ђено је да су комплекси бинуклеарни и предложена је егзо координација макроциклич-
ког лиганда у конформацији лађе. Ко-лиганди су координовани као мост, користећи оба 
атома кисеоника OCO–-групе. Цитотоксична активност Cu(II) комплекса и њихових 
Co(II) аналога, полазних лиганада и стартних соли тестирана је на ћелијским линијама 
аденокарцинома цервикса (HeLa), хроничне мијелогене леукемије (К562), карцинома 
дојке (MDA-MB-453) и неканцерозној ћелијској линији, хуманог ембрионалног плућног 
фибробласта (МРЦ-5). IC50 вредности за Cu(II) комплексе су од 21,60±0,04 до 66,1±0,8, 
а за Co(II) аналоге су у опсегу од 8,8±0,74 до 15,40±1,52. Сва четири комплекса су 
тестирана на антимикробну активност према Staphylococcus aureus, Bacillus subtilis, Esche-
richia coli и Candida albicans. 
(Примљено 10. јула, ревидирано 17. августа, прихваћено 18. августа 2019) 
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